drugset / Trial / NCT07620574
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.
Timeline
- Start
- 2026-05-31
- Primary completion
- 2030-05-31
- Completion
- 2030-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Atezolizumab | Monoclonal antibody | — | — |
| Background | Cabozantinib | Small molecule | — | — |
| Background | Enzalutamide | Other / unclassified | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Zanzalintinib | Small molecule | — | — |